The DOI matches its Crossref record; 373 of the 373 references it cites were found in a registry or an index.
Malignant melanoma: genetics and therapeutics in the genomic era
Open accessAbstract
Cell for cell, probably no human cancer is as aggressive as melanoma. It is among a handful of cancers whose dimensions are reported in millimeters. Tumor thickness approaching 4 mm presents a high risk of metastasis, and a diagnosis of metastatic melanoma carries with it an abysmal median survival of 6–9 mo. What features of this malignancy account for such aggressive behavior? Is it the migratory history of its cell of origin or the programmed adaptation of its differentiated progeny to environmental stress, particularly ultraviolet radiation? While the answers to these questions are far from complete, major strides have been made in our understanding of the cellular, molecular, and genetic underpinnings of melanoma. More importantly, these discoveries carry profound implications for the development of therapies focused directly at the molecular engines driving melanoma, suggesting that we may have reached the brink of an unprecedented opportunity to translate basic science into clinical advances. In this review, we attempt to summarize our current understanding of the genetics and biology of this disease, drawing from expanding genomic information and lessons from development and genetically engineered mouse models. In addition, we look forward toward how these new insights will impact on therapeutic options for metastatic melanoma in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 4×
“…at chromosome 9p21, LOH or mutation at this locus cosegregated with melanoma susceptibility in familial melanoma kindred (Hussussian et al. 1994; Kamb et al. 1994b), and 9p21 homozygous deletions centered on CDKN2A were frequently observed in cancer cell lines of different types (Kamb et al.…”
BackgroundInfluentialDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Molecular classification of cutaneous malignant melanoma by gene expression profiling
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., et al. (2000) · Nature · doi:10.1038/35020115 · Cited by 1,990
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Self-citationGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationSchmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 2×
“Ultimately, elucidation of the role of ARF as a negative regulator of p53 (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) offered a mechanistic explanation for the patterns of genetic mutations in human disease, where the lack of p53 mutation in melanoma reflected…”
BackgroundSelf-citationPten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Mitogen-activated protein kinases in apoptosis regulation
Wada, T., & Penninger, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207556 · Cited by 1,432 · cited 1×
“Moreover, signaling pathways such as the MAP kinase and PI3 kinase/AKT cascades that undergo aberrant activation in melanoma produce well-characterized tumor survival effects (for recent reviews, see Wada and Penninger 2004; Kharas and Fruman 2005).”
BackgroundBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Self-citationA tumorigenic subpopulation with stem cell properties in melanomas
Fang, D., Nguyen, T. K., Leishear, K., Finko, R., Kulp, A. N., Hotz, S., Van Belle, P. A., Xu, X., Elder, D. E., & Herlyn, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1343 · Cited by 1,280
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Malignant glioma: genetics and biology of a grave matter
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001) · Genes & Development · doi:10.1101/gad.891601 · Cited by 1,229
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 2×
“While these biological outcomes indicate distinct roles for NRAS and BRAF activation in melanoma genesis, some functional overlap is suggested by the predominantly nonconcurrent occurrence of activated NRAS and B-RAF alleles in melanoma and other tumor types (Davies et al. 2002; Rajagopalan et al. 2002; Goel et al. 20…”
BackgroundStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrímsson, E., Copeland, N. G., Jenkins, N. A., & Arnheiter, H. (1993) · Cell · doi:10.1016/0092-8674(93)90429-t · Cited by 1,094
SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans
Lamason, R. L., Mohideen, M.-A. P. K., Mest, J. R., Wong, A. C., Norton, H. L., Aros, M. C., Jurynec, M. J., Mao, X., Humphreville, V. R., Humbert, J. E., et al. (2005) · Science · doi:10.1126/science.1116238 · Cited by 1,043
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“Blockade of CTLA-4 function by these antibodies can trigger or exacerbate autoimmunity, but also enhances immune-mediated tumor rejection in mouse models (Leach et al. 1996; van Elsas et al. 1999; Egen et al. 2002).”
BackgroundAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Valverde, P., Healy, E., Jackson, I., Rees, J. L., & Thody, A. J. (1995) · Nature Genetics · doi:10.1038/ng1195-328 · Cited by 999
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma
Weeraratna, A. T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., & Trent, J. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00045-4 · Cited by 959
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Dominant role of the niche in melanocyte stem-cell fate determination
Nishimura, E. K., Jordan, S. A., Oshima, H., Yoshida, H., Osawa, M., Moriyama, M., Jackson, I. J., Barrandon, Y., Miyachi, Y., & Nishikawa, S.-I. (2002) · Nature · doi:10.1038/416854a · Cited by 901
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899
Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
The pathogenesis of melanoma induced by ultraviolet radiation
Gilchrest, B. A., Eller, M. S., Geller, A. C., & Yaar, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401707 · Cited by 876
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi
Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Abeni, D., Boyle, P., & Melchi, C. F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.015 · Cited by 842
Apoptosis and melanoma chemoresistance
Soengas, M. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206454 · Cited by 826
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“Germline mutations of CDK4, an Rb-kinase that is inhibited by INK4A, have also been identified in melanoma-prone kindreds (Wolfel et al. 1995; Zuo et al. 1996; Soufir et al. 1998; Tsao et al. 1998; Molven et al. 2005).”
BackgroundCyclic AMP a Key Messenger in the Regulation of Skin Pigmentation
BUSCÀ, R., & BALLOTTI, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130203.x · Cited by 806
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Zanetti, R., Masini, C., Boyle, P., & Melchi, C. F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.034 · Cited by 787
McGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y.-L., Ramaswamy, S., Avery, W., Ding, H.-F., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00762-6 · Cited by 760
Self-citationMechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche
Nishimura, E. K., Granter, S. R., & Fisher, D. E. (2005) · Science · doi:10.1126/science.1099593 · Cited by 750
Self-citationOnken, M. D., Worley, L. A., Ehlers, J. P., & Harbour, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1750 · Cited by 750
Hemesath, T. J., Steingrímsson, E., McGill, G., Hansen, M. J., Vaught, J., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., Jenkins, N. A., & Fisher, D. E. (1994) · Genes & Development · doi:10.1101/gad.8.22.2770 · Cited by 673
Self-citationDeterminants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664 · cited 8×
“2002), mutations in BRAF have been detected in a variety of tumor types, with the highest incidence in melanoma (ranging from 27% to 70%) (Maldonado et al. 2003; Pollock et al. 2003; Uribe et al. 2003; Daniotti et al. 2004; Kumar et al. 2004; Shinozaki et al. 2004; Libra et al. 2005), followed by papillary thyroid tum…”
BackgroundInfluentialPatton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., Berghmans, S., Mayhall, E. A., Traver, D., Fletcher, C. D. M., et al. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.031 · Cited by 664
Self-citationRinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes
Hemesath, T. J., Price, E. R., Takemoto, C., Badalian, T., & Fisher, D. E. (1998) · Nature · doi:10.1038/34681 · Cited by 630
Self-citationLadanyi, M., Lui, M. Y., Antonescu, C. R., Krause-Boehm, A., Meindl, A., Argani, P., Healey, J. H., Ueda, T., Yoshikawa, H., Meloni-Ehrig, A., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204074 · Cited by 625
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cavé, H., Verloes, A., Okamoto, N., Hennekam, R. C. M., Gillessen-Kaesbach, G., Wieczorek, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1749 · Cited by 599
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma
Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., Sayegh, M. H., Sadee, W., & Frank, M. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3327 · Cited by 574
Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568 · cited 4×
“…et al. 2001; Sharpless et al. 2001, GENES & DEVELOPMENT 2151 2002), this Ink4a-dependent susceptibility was significantly enhanced in the setting of Arf haploinsufficiency (Krimpenfort et al. 2001), arguing for an independent contribution from Arf in Ink4a/Arf-mediated melanoma suppression.”
BackgroundInfluentialMortality From Second Tumors Among Long-Term Survivors of Retinoblastoma
Eng, C., Li, F. P., Abramson, D. H., Ellsworth, R. M., Wong, F. L., Goldman, M. B., Seddon, J., Tarbell, N., & Boice, J. D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.14.1121 · Cited by 568
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P., Polyzos, A., Papadopoulos, O., Stratigos, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053007 · Cited by 566
Second primary neoplasms in patients with retinoblastoma
Draper, G. J., Sanders, B. M., & Kingston, J. E. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.110 · Cited by 554
Wu, M., Hemesath, T. J., Takemoto, C. M., Horstmann, M. A., Wells, A. G., Price, E. R., Fisher, D. Z., & Fisher, D. E. (2000) · Genes & Development · doi:10.1101/gad.14.3.301 · Cited by 527
Self-citationBastian, B. C., LeBoit, P. E., Hamm, H., Bröcker, E.-B., & Pinkel, D. (1998) · PubMed · Cited by 513
Microphthalmia Gene Product as a Signal Transducer in cAMP-Induced Differentiation of Melanocytes
Bertolotto, C., Abbe, P., Hemesath, T. J., Bille, K., Fisher, D. E., Ortonne, J.-P., & Ballotti, R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.142.3.827 · Cited by 512
Self-citationPrognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507
Palmer, J. S., Duffy, D. L., Box, N. F., Aitken, J. F., O'Gorman, L. E., Green, A. C., Hayward, N. K., Martin, N. G., & Sturm, R. A. (2000) · The American Journal of Human Genetics · doi:10.1086/302711 · Cited by 503 · cited 4×
“…and D294H) have been associated with the so-called Red Hair Color (RHC) phenotype (Box et al. 1997, 2001; Smith et al. 1998; Flanagan et al. 2000; Palmer et al. 2000; Bastiaens et al. 2001a,b), characteristic of individuals with red hair, fair complexion, an inability to tan, and a tendency to…”
BackgroundInfluentialControl of neural crest cell fate by the Wnt signalling pathway
Dorsky, R. I., Moon, R. T., & Raible, D. W. (1998) · Nature · doi:10.1038/24620 · Cited by 501
Steingrímsson, E., Moore, K. J., Lamoreux, M. L., Ferré-D'Amaré, A. R., Burley, S. K., Sanders Zimring, D. C., Skow, L. C., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., et al. (1994) · Nature Genetics · doi:10.1038/ng1194-256 · Cited by 493
Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2749 · Cited by 490
Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
PTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Telomeres, stem cells, senescence, and cancer
Sharpless, N. E., & DePinho, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20761 · Cited by 473
Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome
Bondurand, N. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.13.1907 · Cited by 467
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Mutations and Copy Number Increase of HRAS in Spitz Nevi with Distinctive Histopathological Features
Bastian, B. C., LeBoit, P. E., & Pinkel, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64609-3 · Cited by 455
High Risk of Malignant Melanoma in Melanoma-Prone Families with Dysplastic Nevi
GREENE, M. H., CLARK, W. H., TUCKER, M. A., KRAEMER, K. H., ELDER, D. E., & FRASER, M. C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-4-458 · Cited by 455
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Bentley, N. J., Eisen, T., & Goding, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.7996 · Cited by 450
Activating mutations for the Met tyrosine kinase receptor in human cancer
Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., & Vande Woude, G. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11445 · Cited by 442
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation
Gupta, P. B., Kuperwasser, C., Brunet, J.-P., Ramaswamy, S., Kuo, W.-L., Gray, J. W., Naber, S. P., & Weinberg, R. A. (2005) · Nature Genetics · doi:10.1038/ng1634 · Cited by 439
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
The gene expression signatures of melanoma progression
Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B. L., Federman, S., Miller, J. R., Allen, R. E., Singer, M. I., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501564102 · Cited by 433
B-RAF is a therapeutic target in melanoma
Karasarides, M., Chiloeches, A., Hayward, R., Niculescu-Duvaz, D., Scanlon, I., Friedlos, F., Ogilvie, L., Hedley, D., Martin, J., Marshall, C. J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207785 · Cited by 426
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., Nishimura, E. K., Golub, T. R., & Fisher, D. E. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.014 · Cited by 421
Self-citationAUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMA
Lázár-Molnár, E., Hegyesi, H., Tóth, S., & Falus, A. (2000) · Cytokine · doi:10.1006/cyto.1999.0614 · Cited by 416
CTLA-4 in autoimmune diseases – a general susceptibility gene to autoimmunity?
Kristiansen, O., Larsen, Z., & Pociot, F. (2000) · Genes & Immunity · doi:10.1038/sj.gene.6363655 · Cited by 414
Kennedy, C., ter Huurne, J., Berkhout, M., Gruis, N., Bastiaens, M., Bergman, W., Willemze, R., & Bouwes Bavinck, J. N. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01421.x · Cited by 407
Akt Blocks Breast Cancer Cell Motility and Invasion through the Transcription Factor NFAT
Yoeli-Lerner, M., Yiu, G. K., Rabinovitz, I., Erhardt, P., Jauliac, S., & Toker, A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.10.033 · Cited by 407
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
Self-citationSlug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma
Wu, W.-S., Heinrichs, S., Xu, D., Garrison, S. P., Zambetti, G. P., Adams, J. M., & Look, A. T. (2005) · Cell · doi:10.1016/j.cell.2005.09.029 · Cited by 398
Pax3 functions at a nodal point in melanocyte stem cell differentiation
Lang, D., Lu, M. M., Huang, L., Engleka, K. A., Zhang, M., Chu, E. Y., Lipner, S., Skoultchi, A., Millar, S. E., & Epstein, J. A. (2005) · Nature · doi:10.1038/nature03292 · Cited by 397
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression
Carreira, S., Goodall, J., Aksan, I., La Rocca, S. A., Galibert, M.-D., Denat, L., Larue, L., & Goding, C. R. (2005) · Nature · doi:10.1038/nature03269 · Cited by 395
Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene
Kim, M., Gans, J. D., Nogueira, C., Wang, A., Paik, J.-H., Feng, B., Brennan, C., Hahn, W. C., Cordon-Cardo, C., Wagner, S. N., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.008 · Cited by 392
Self-citationExamination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 392
Soufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
Neonatal sunburn and melanoma in mice
Noonan, F. P., Recio, J. A., Takayama, H., Duray, P., Anver, M. R., Rush, W. L., De Fabo, E. C., & Merlino, G. (2001) · Nature · doi:10.1038/35095108 · Cited by 386
The coat colours of mice. A model for mammalian gene action and interaction.
Silvers, W. K. (1979) · Springer eBooks · Cited by 384
Potterf, S. B., Furumura, M., Dunn, K. J., Arnheiter, H., & Pavan, W. J. (2000) · Human Genetics · doi:10.1007/s004390000328 · Cited by 379
Eton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.044 · Cited by 370
Yasumoto, K., Yokoyama, K., Shibata, K., Tomita, Y., & Shibahara, S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8058 · Cited by 368
Reprogramming of a melanoma genome by nuclear transplantation
Hochedlinger, K., Blelloch, R., Brennan, C., Yamada, Y., Kim, M., Chin, L., & Jaenisch, R. (2004) · Genes & Development · doi:10.1101/gad.1213504 · Cited by 367
Self-citationHuang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.-D., Gudas, J. M., & Bar-Eli, M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64164-8 · Cited by 361
The genetics of pigmentation: from fancy genes to complex traits
Barsh, G. S. (1996) · Trends in Genetics · doi:10.1016/0168-9525(96)10031-7 · Cited by 360
Lineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
Self-citationClark, J., Lu, Y.-J., Sidhar, S. K., Parker, C., Gill, S., Smedley, D., Hamoudi, R., Linehan, W. M., Shipley, J., & Cooper, C. S. (1997) · Oncogene · doi:10.1038/sj.onc.1201394 · Cited by 344
V599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
Characterization of Melanocyte Stimulating Hormone Receptor Variant Alleles in Twins with Red Hair
Box, N. F., Wyeth, J. R., O'Gorman, L. E., Martin, N. G., & Sturm, R. A. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1891 · Cited by 340
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Dranoff, G. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18813.x · Cited by 334
Mackenzie, M. A. F., Jordan, S. A., Budd, P. S., & Jackson, I. J. (1997) · Developmental Biology · doi:10.1006/dbio.1997.8738 · Cited by 331
Eigentler, T. K., Caroli, U. M., Radny, P., & Garbe, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01280-4 · Cited by 324
Tschentscher, F., Hüsing, J., Hölter, T., Kruse, E., Dresen, I. G., Jöckel, K., Anastassiou, G., Schilling, H., Bornfeld, N., Horsthemke, B., et al. (2003) · PubMed · Cited by 323
Induction of Melanocyte-specific Microphthalmia-associated Transcription Factor by Wnt-3a
Takeda, K., Yasumoto, K.-I., Takada, R., Takada, S., Watanabe, K.-I., Udono, T., Saito, H., Takahashi, K., & Shibahara, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000113200 · Cited by 322
Dai, D. L., Martinka, M., & Li, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.168 · Cited by 318
Du, J., Miller, A. J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., & Fisher, D. E. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63657-7 · Cited by 313
Self-citationLifetime Risks of Common Cancers Among Retinoblastoma Survivors
Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., & Peto, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh058 · Cited by 312
Loss of PTEN promotes tumor development in malignant melanoma.
Stahl, J. M., Cheung, M., Sharma, A. K., Trivedi, N. R., Shanmugam, S., & Robertson, G. P. (2003) · PubMed · Cited by 310
MC1R Genotype Modifies Risk of Melanoma in Families Segregating CDKN2A Mutations
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., & Hayward, N. K. (2001) · The American Journal of Human Genetics · doi:10.1086/323412 · Cited by 310
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Ackermann, J., Frutschi, M., Kaloulis, K., McKee, T., Trumpp, A., & Beermann, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2970 · Cited by 306
The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development
Sibilia, M., Fleischmann, A., Behrens, A., Stingl, L., Carroll, J., Watt, F. M., Schlessinger, J., & Wagner, E. F. (2000) · Cell · doi:10.1016/s0092-8674(00)00026-x · Cited by 304
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
Self-citationShackleton, R. G. (2005) · Cited by 294
Widlund, H. R., Horstmann, M. A., Price, E. R., Cui, J., Lessnick, S. L., Wu, M., He, X., & Fisher, D. E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200202049 · Cited by 291
Self-citationEpistatic relationship between Waardenburg Syndrome genes MITF and PAX3
Watanabe, A., Takeda, K., Ploplis, B., & Tachibana, M. (1998) · Nature Genetics · doi:10.1038/ng0398-283 · Cited by 290
Rimm, D. L., Caca, K., Hu, G., Harrison, F. B., & Fearon, E. R. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65278-9 · Cited by 283
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281
Dorsky, R. I., Raible, D. W., & Moon, R. T. (2000) · Genes & Development · doi:10.1101/gad.14.2.158 · Cited by 279
Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation
Flanagan, N. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.17.2531 · Cited by 278
Therapeutic and diagnostic implications of Hsp90 activation
Kamal, A., Boehm, M. F., & Burrows, F. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.04.006 · Cited by 278
Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma
Liu, L., Dilworth, D., Gao, L., Monzon, J., Summers, A., Lassam, N., & Hogg, D. (1999) · Nature Genetics · doi:10.1038/5082 · Cited by 276
Degenerative Disorders Caused by Bcl-2 Deficiency Prevented by Loss of Its BH3-Only Antagonist Bim
Bouillet, P., Cory, S., Zhang, L.-C., Strasser, A., & Adams, J. M. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00083-1 · Cited by 274
Sidhar, S. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.9.1333 · Cited by 272
Otsuka, T., Takayama, H., Sharp, R., Celli, G. B., LaRochelle, W. J., Bottaro, D. P., Ellmore, N., Vieira, W., Owens, J. W., Anver, M. R., et al. (1998) · PubMed · doi:10.5281/zenodo.894795 · Cited by 268
Meier, F. (2005) · Frontiers in Bioscience · doi:10.2741/1755 · Cited by 267
Loercher, A. E., Tank, E. M. H., Delston, R. B., & Harbour, J. W. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200410115 · Cited by 266
SLUG (SNAI2) deletions in patients with Waardenburg disease
Sanchez-Martin, M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.25.3231 · Cited by 259
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B., Slade, H. B., Gollnick, H., & Schon, M. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg016 · Cited by 258
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Richards, J. M., Mehta, N., Ramming, K., & Skosey, P. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1338 · Cited by 257
Bastiaens, M. T., Huurne, J. A. C. T., Kielich, C., Gruis, N. A., Westendorp, R. G. J., Vermeer, B. J., & Bavinck, J. N. B. (2001) · The American Journal of Human Genetics · doi:10.1086/319500 · Cited by 249
Melanocortin 1 Receptor Variants in an Irish Population
Smith, R., Healy, E., Siddiqui, S., Flanagan, N., Steijlen, P. M., Rosdahl, I., Jacques, J. P., Rogers, S., Turner, R., Jackson, I. J., et al. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00252.x · Cited by 248
Davis, I. J., Hsi, B.-L., Arroyo, J. D., Vargas, S. O., Yeh, Y. A., Motyckova, G., Valencia, P., Perez-Atayde, A. R., Argani, P., Ladanyi, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931430100 · Cited by 247
Self-citationda Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Mansky, K. C., Sankar, U., Han, J., & Ostrowski, M. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111696200 · Cited by 243
Grem, J. L., Morrison, G., Guo, X.-D., Agnew, E., Takimoto, C. H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.085 · Cited by 242
Xu, W., Gong, L., Haddad, M. M., Bischof, O., Campisi, J., Yeh, E. T. H., & Medrano, E. E. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4803 · Cited by 241
The melanocortin-1-receptor gene is the major freckle gene
Bastiaens, M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1701 · Cited by 236
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Hoeflich, K. P., Gray, D. C., Eby, M. T., Tien, J. Y., Wong, L., Bower, J., Gogineni, A., Zha, J., Cole, M. J., Stern, H. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2720 · Cited by 232
Willmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
Kumar, R., Angelini, S., Snellman, E., & Hemminki, K. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22225.x · Cited by 229
Argani, P., Hawkins, A., Griffin, C. A., Goldstein, J. D., Haas, M., Beckwith, J. B., Mankinen, C. B., & Perlman, E. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64680-9 · Cited by 228
Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling
Yasumoto, K.-I. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2703 · Cited by 228
Steingrímsson, E., Tessarollo, L., Pathak, B., Hou, L., Arnheiter, H., Copeland, N. G., & Jenkins, N. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072071099 · Cited by 227
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors
Nakahara, M., Isozaki, K., Hirota, S., Miyagawa, J.-I., Hase-Sawada, N., Taniguchi, M., Nishida, T., Kanayama, S., Kitamura, Y., Shinomura, Y., et al. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70079-4 · Cited by 227
Price, E. R., Horstmann, M. A., Wells, A. G., Weilbaecher, K. N., Takemoto, C. M., Landis, M. W., & Fisher, D. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.33042 · Cited by 225
Self-citationSkin colour and skin cancer –MC1R, the genetic link
Sturm, R. A. (2002) · Melanoma Research · doi:10.1097/00008390-200209000-00001 · Cited by 224
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
Risk of cutaneous melanoma associated with a family history of the disease
Ford, D., Bliss, J. M., Swerdlow, A. J., Armstrong, B. K., Franceschi, S., Green, A., Holly, E. A., Mack, T., Mackie, R. M., Østerlind, A., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620403 · Cited by 216
Miller, A. J., Du, J., Rowan, S., Hershey, C. L., Widlund, H. R., & Fisher, D. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2440 · Cited by 214
Self-citationLi, G., Schaider, H., Satyamoorthy, K., Hanakawa, Y., Hashimoto, K., & Herlyn, M. (2001) · Oncogene · doi:10.1038/sj.onc.1205034 · Cited by 212 · cited 1×
“Although MET is normally activated in a paracrine manner, autocrine activation of HGF–MET has been described in melanoma progression (Li et al. 2001; for review, see Vande Woude et al. 1997).”
BackgroundIncidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1169-3 · Cited by 212
Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon‐Cardo, C., McNutt, N. S., Bressler, J., & Andreeff, M. (1989) · PubMed · Cited by 212
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz, F., Rubin, B. P., Wilson, D. J., Town, A., Schroeder, A., Haley, A., Bainbridge, T., Heinrich, M. C., & Corless, C. L. (2003) · PubMed · Cited by 208
Kuiper, R. P. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg178 · Cited by 208
Kunisada, T., Lu, S.-Z., Yoshida, H., Nishikawa, S., Nishikawa, S.-I., Mizoguchi, M., Hayashi, S.-I., Tyrrell, L., Williams, D. A., Wang, X., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1565 · Cited by 208
Weterman, M. A. J., Wilbrink, M., & van Kessel, A. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15294 · Cited by 206
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone, K., Belle, P. A. V., Elenitsas, R., & Elder, D. (1997) · PubMed · Cited by 206
Natali, P., Nicotra, M., Di Renzo, M., Prat, M., Bigotti, A., Cavaliere, R., & Comoglio, P. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.422 · Cited by 205
Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol
Shapiro, G. I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040020 · Cited by 203
Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers
Davis, I. J., Kim, J. J., Ozsolak, F., Widlund, H. R., Rozenblatt-Rosen, O., Granter, S. R., Du, J., Fletcher, J. A., Denny, C. T., Lessnick, S. L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.021 · Cited by 202
Self-citationFitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200
CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., & Hayward, N. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.446 · Cited by 200
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Chudnovsky, Y., Adams, A. E., Robbins, P. B., Lin, Q., & Khavari, P. A. (2005) · Nature Genetics · doi:10.1038/ng1586 · Cited by 198
Classification of Clear-Cell Sarcoma as a Subtype of Melanoma by Genomic Profiling
Segal, N. H., Pavlidis, P., Noble, W. S., Antonescu, C. R., Viale, A., Wesley, U. V., Busam, K., Gallardo, H., DeSantis, D., Brennan, M. F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.108 · Cited by 197
Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196
Takayama, H., La Rochelle, W. J., Anver, M., Bockman, D. E., & Merlino, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5866 · Cited by 195
Cited by
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Self-citationIdentification of cells initiating human melanomas
Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L. M., Weishaupt, C., et al. (2008) · Nature · doi:10.1038/nature06489 · Cited by 1,415
Melanocyte biology and skin pigmentation
Lin, J. Y., & Fisher, D. E. (2007) · Nature · doi:10.1038/nature05660 · Cited by 1,379
Self-citationBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Central role of p53 in the suntan response and pathologic hyperpigmentation
Cui, R., Widlund, H. R., Feige, E., Lin, J. Y., Wilensky, D. L., Igras, V. E., D'Orazio, J., Fung, C. Y., Schanbacher, C. F., Granter, S. R., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.045 · Cited by 657
“, 2002) since the entire pigmentation machinery, including tyrosinase, is thought to be transcriptionally activated by MITF (Chin et al., 2006).”
Self-citation
Metadata
- Authors
- Chin, L., Garraway, L. A., & Fisher, D. E.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2006-08-15
- Volume
- 20
- Issue
- 16
- Pages
- 2149-2182
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2161275429
- Cited by
- 511
- References
- 373
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.